First trimester risk assessment for trisomy 21 in twin pregnancies combining nuchal translucency and first trimester biochemical markers

2012 ◽  
Vol 32 (10) ◽  
pp. 927-932 ◽  
Author(s):  
Pilar Prats ◽  
Ignacio Rodríguez ◽  
Carmina Comas ◽  
Bienvenido Puerto
2016 ◽  
Vol 0 (0) ◽  
Author(s):  
Niels Tørring ◽  
Carlos Aulesa ◽  
Bernd Eiben ◽  
Mª José Ferri ◽  
Kypros H. Nicolaides ◽  
...  

AbstractScreening for fetal trisomy 21 (T21) in the first trimester includes analysis of the serological markers pregnancy-associated plasma protein A (PAPP-A) and free β-choriogonadotropin (free βhCG). With the recent launch of these assays on the cobas e and Elecsys platforms, we investigated their clinical and analytical performance.We conducted a multicenter study in 5397 pregnancies including 108 cross-sectional collected repository cases with verified fetal T21 at 8–14 weeks of gestation. A technical validation of the Roche ElecsysThe imprecision of the Elecsys free βhCG and PAPP-A assays was between 1.0% and 2.8%, and both assays showed correlation to Kryptor (free βhCG 0.981; PAPP-A 0.987), AutoDELFIA (free βhCG 0.995; PAPP-A 0.979) and IMMULITE assays (free βhCG 0.983; PAPP-A 0.983). With a cut off at 1:300 the overall sensitivity of the screening including nuchal translucency reached 94% for a 3% false positive rate.The Roche Elecsys free βhCG and PAPP-A are suitable and reliable assays for first trimester T21 risk assessment. Both assays were approved and recommended by the FMF.


2015 ◽  
Vol 86 (5) ◽  
pp. 362-365
Author(s):  
Şevki Çelen ◽  
Yaprak Engin-Üstün ◽  
Figen Türkçapar ◽  
Ayla Aktulay ◽  
Nafiye Yılmaz ◽  
...  

2018 ◽  
Vol 5 (3) ◽  
pp. 139-143
Author(s):  
Sarang Younesi ◽  
Shahram Savad ◽  
Soudeh Ghafouri-Fard ◽  
Mohammad Mahdi Taheri-Amin ◽  
Pourandokht Saadati ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document